What changed
$OGN — BUY 📊
Organon & Co.
🎯 Q2 2026 | Rev $1B | EPS $0.71 vs $0.85 🔴
💡 Consensus now expects continued earnings deterioration and a possible dividend cut, but we believe the miss was partly due to transitory factors and that management will reaffirm guidance, causing a sharp rebound in sentiment.
📉 Reward/risk: 1.8:1
🏢 Business Quality: 5/10 - Stable cash flows from established brands offset by high leverage and low growth; moderate quality.
📊 Valuation: cheap - Trading at 4.7x annualized P/E and ~5.7x EV/EBITDA, well below pharma peers at 10-12x, reflecting pessimism. Normalized FCF yield is >20%.
🔮 Catalyst: Q2 2026 earnings report
💰 Entry: $13.45, stop $11.5, target $17
⚖️ Buy OGN at $13.45 for a 3-month recovery play: deep value, near-term catalyst.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/OGN0624